Despite Inflationary Headwinds, Chinese CRO WuXi PharmaTech Set To Ride Wave Of Global Outsourcing
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Leading Chinese contract research organization WuXi PharmaTech will face inflationary pressure on profits this year, but stepped-up outsourcing of research to China by international pharmaceutical players and the Shanghai-based firm's expanding range of services are likely to ensure strong earnings through 2011 and beyond, according to a prominent analyst who monitors the country's healthcare sector
You may also be interested in...
The Rise Of The Chinese CRO: New Models For An Emerging Player
SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands
The Rise Of The Chinese CRO: New Models For An Emerging Player
SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands
Vertex And Merck Neck-To-Neck In HCV Race
Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.